Notable Labs to Participate in JMP Securities Hematology and Oncology Summit
04. Dezember 2023 16:30 ET
|
Notable Labs
FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for...
Notable Labs Announces Filing of Form 10-Q for Third Quarter 2023
14. November 2023 16:15 ET
|
Notable Labs
-Summarizes third quarter 2023 financials of pre-Merger VBLT as of September 30th- -Third quarter financial information of Notable Labs, Inc. and pro forma combined financial information of Notable...
Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML
09. November 2023 16:05 ET
|
Notable Labs
– Article Published in November 9th Issue of ASCO’s Journal of Clinical Oncology Precision Oncology (JCO PO) – – Results highlight PPMP as a tool for identifying most promising drug combinations for...
Notable Labs Closes Merger Transaction With VBL Therapeutics
16. Oktober 2023 13:01 ET
|
Notable Labs
- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned...
Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress
09. Juni 2023 08:00 ET
|
Notable Labs
– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to regimens currently used in JMML – FOSTER...
Notable Labs to Present Predictive Precision Medicine Platform (PPMP) Data in Juvenile Myelomonocytic Leukemia (JMML) at European Hematology Association (EHA) Hybrid Congress June 8 – 15, 2023
17. Mai 2023 07:00 ET
|
Notable Labs
FOSTER CITY, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients,...
Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting
18. April 2023 09:00 ET
|
Notable Labs
- 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning - - Fourth clinical validation study of Predictive Precision Medicine Platform - FOSTER CITY,...
Notable Labs to Present Results from Clinical Platform Validation Study at the 2023 American Association for Cancer Research (AACR) Annual Meeting
14. März 2023 16:30 ET
|
Notable Labs
FOSTER CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients,...
Notable to Host July 23 Webinar with Stanford Cancer Institute and MDS Foundation: Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes
13. Juli 2020 11:00 ET
|
Notable Labs
FOSTER CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...
Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer
08. Juli 2020 11:00 ET
|
Notable Labs
FOSTER CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...